<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Everolimus (RAD001, Novartis), an oral derivative of <z:chebi fb="0" ids="9168">rapamycin</z:chebi>, inhibits the mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR), which regulates many aspects of cell growth and division </plain></SENT>
<SENT sid="1" pm="."><plain>A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or <z:e sem="disease" ids="C1335724" disease_type="Neoplastic Process" abbrv="">refractory hematologic malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: Two dose levels (5 and 10 mg orally once daily continuously) were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Twenty-seven patients (9 <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, 5 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 6 B-<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, 4 mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 1 <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, 1 natural killer cell/T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and 1 T-cell prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>) received everolimus </plain></SENT>
<SENT sid="4" pm="."><plain>No dose-limiting toxicities were observed </plain></SENT>
<SENT sid="5" pm="."><plain>Grade 3 potentially drug-related toxicities included <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (22%), <z:hpo ids='HP_0002148'>hypophosphatemia</z:hpo> (7%), <z:mp ids='MP_0002899'>fatigue</z:mp> (7%), <z:hpo ids='HP_0002039'>anorexia</z:hpo> (4%), and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (4%) </plain></SENT>
<SENT sid="6" pm="."><plain>One patient developed a cutaneous leukocytoclastic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> requiring a skin graft </plain></SENT>
<SENT sid="7" pm="."><plain>One patient with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts achieved a major platelet response of over 3-month duration </plain></SENT>
<SENT sid="8" pm="."><plain>A second patient with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts showed a minor platelet response of 25-day duration </plain></SENT>
<SENT sid="9" pm="."><plain>Phosphorylation of downstream targets of mTOR, eukaryotic initiation factor 4E-binding protein 1, and/or, p70 S6 kinase, was inhibited in six of nine patient samples, including those from the patient with a major platelet response </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Everolimus is well tolerated at a daily dose of 10 mg daily and may have activity in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted </plain></SENT>
</text></document>